Salix Pharmaceuticals, Ltd. Stock

Stocks

17/03/15	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
16/03/15	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
16/03/15	Wall St. bounces as dollar drops, Fed worries ease	RE
16/03/15	Endo : withdraws offer for Salix	RE
11/03/15	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
24/02/15	Shire : buys Meritage Pharma for at least $70 million	RE
24/02/15	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
24/02/15	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
23/02/15	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
22/02/15	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

11/03/15	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
03/03/15	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
27/02/15	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
26/02/15	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5% Convertible Senior Notes Due 2019	BU
26/02/15	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75% Convertible Senior Notes Due 2015	BU

01/04/15	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
30/03/15	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
16/03/15	Le recul du dollar a favorisé le rebond de Wall Street
16/03/15	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
16/03/15	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	01/01/2018
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
MERCK & CO., INC.	-1.32%	+1.74%	+77.46%	+39.27%	371B
MERCK KGAA	-0.55%	-2.81%	+23.32%	-19.32%	68.64B
HALOZYME THERAPEUTICS, INC.	-0.51%	+3.47%	+47.06%	+181.53%	12.51B
KYOWA KIRIN CO., LTD.	-0.98%	-11.91%	-9.00%	-9.40%	8.06B
SK BIOPHARMACEUTICALS CO., LTD.	-1.85%	-2.63%	-22.16%	+5.72%	5.04B
YUHAN CORPORATION	-0.86%	-3.58%	-32.18%	+18.68%	4.51B
BETTA PHARMACEUTICALS CO., LTD.	-1.39%	-4.32%	-34.69%	-0.14%	3.07B
SUPERNUS PHARMACEUTICALS, INC.	-1.00%	-1.54%	-5.37%	+44.81%	2.53B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.77%	-2.51%	-24.93%	-16.23%	2B
Average	-0.92%	-2.20%	+2.17%	+27.21%	53.03B
Weighted average by Cap.	-1.18%	+0.48%	+63.74%	+32.75%